Literature DB >> 18435964

Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation.

Chris van der Lee1, Bas Scholzel, Jurriën M ten Berg, Marcel L Geleijnse, Herman H Idzerda, Ron T van Domburg, Wim B Vletter, Patrick W Serruys, Folkert J ten Cate.   

Abstract

This study was conducted to assess outcomes after percutaneous transluminal septal myocardial ablation (PTSMA) treatment in 131 patients (mean age 56+/-16 years) with obstructive hypertrophic cardiomyopathy. In-hospital and follow-up complications as well as late PTSMA failure (defined as unsatisfactory clinical outcome and a significant residual outflow tract gradient, necessitating reintervention) were noted. Baseline clinical, echocardiographic, and PTSMA characteristics were examined as determinants of outcomes. Also, the effect of ethanol volume and the role of a learning curve were investigated. PTSMA was successful in 90% of the patients. In-hospital and follow-up cardiac events were noted in 20 patients, including cardiac death (in-hospital n=4, follow-up n=1), acute myocardial infarction due to ethanol leakage (n=1), coronary dissection (n=2), nonfatal cardiac tamponade (n=1), and permanent pacemaker (n=6) or cardiac defibrillator (in-hospital n=4, follow-up n=1) implantation. Late PTSMA failure was noted in 12 patients. All baseline characteristics were comparable between successful and failed PTSMA. Ethanol volume was related to peak creatinine kinase value (p<0.0001) but not to late PTSMA failure or greater need for pacemaker implantation. Late PTSMA failure occurred more frequently in PTSMA procedures performed in the early, less experienced time period (p<0.001). In conclusion, this study confirms that PTSMA, although effective, has a relatively high complication rate. Late PTSMA failure could not be predicted by baseline characteristics but could partially be explained by a learning-curve effect. This finding implies that PTSMA procedures should be restricted to experienced centers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18435964     DOI: 10.1016/j.amjcard.2008.01.003

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Basal infarct location but not larger infarct size is associated with a successful outcome after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: a cardiovascular magnetic resonance imaging study.

Authors:  Robbert C Steggerda; Christiane A Geluk; Wessel Brouwer; Albert C van Rossum; Jurriën M Ten Berg; Maarten P van den Berg
Journal:  Int J Cardiovasc Imaging       Date:  2015-02-01       Impact factor: 2.357

2.  Microvascular permeability changes might explain cardiac tamponade after alcohol septal ablation for hypertrophic cardiomyopathy.

Authors:  Jen-Te Hsu; Ju-Feng Hsiao; Jung-Jung Chang; Chang-Min Chung; Shih-Tai Chang; Kuo-Li Pan
Journal:  Tex Heart Inst J       Date:  2014-04-01

3.  Incidence of Atrial Fibrillation following Alcohol Septal Ablation for Hypertrophic Cardiomyopathy.

Authors:  Travis J Moss; Matthew M Zipse; Mori J Krantz; William H Sauer; Ernesto E Salcedo; Joseph L Schuller
Journal:  Ann Noninvasive Electrocardiol       Date:  2016-03-11       Impact factor: 1.468

4.  Predictors of outcome after alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Special interest for the septal coronary anatomy.

Authors:  R C Steggerda; J C Balt; K Damman; M P van den Berg; J M Ten Berg
Journal:  Neth Heart J       Date:  2013-11       Impact factor: 2.380

Review 5.  Intervention in HCM: patient selection, procedural approach and emerging techniques in alcohol septal ablation.

Authors:  Robert M Cooper; Adeel Shahzad; Rodney H Stables
Journal:  Echo Res Pract       Date:  2014-10-30

Review 6.  Twenty Years of Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Angelos G Rigopoulos; Hubert Seggewiss
Journal:  Curr Cardiol Rev       Date:  2016
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.